FAST NEWS: Investment Loss Undermines Simcere Pharma’s Profit
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) on Wednesday reported its revenue grew 27.3% to 2.7 billion yuan ($389 million) in the first half of the year, while its net profit…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
